Hepatocyte transplantation (HT) is attractive option for urea cycle disorder and acute liver failure. HT has the benefit of non-invasive treatment, availability of hepatocyte isolated from marginal donors and cryopreserved hepatocytes at the time of need. On the other hand, the disadvantages of HT are injury of hepatocytes after thawing, difficulty of monitoring acute cellular rejection after HT, and limited donor source for HT. We experienced HT for neonatal ornithine transcarbamylase deficiency patient using hepatocytes from living donor for the fi rst case in the world. In our study, hepatocytes were isolated from the redundant liver of reduced left lateral segment graft from living donor. The quality of hepatocytes from living donor is better than that from deceased donor. The patient underwent living donor liver transplantation from his mother 5 months after HT.
